search
Back to results

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Primary Purpose

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma

Status
Withdrawn
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
TAZEMETOSTAT
Zandelisib
Sponsored by
Jacob Soumerai, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Relapsed Follicular Lymphoma focused on measuring Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Participants must have biopsy-proven relapsed or refractory FL grade 1-2 or 3A by WHO criteria. Participants must require therapy based on: symptomatic disease, threatened end-organ dysfunction, compressive disease, cytopenias secondary to lymphoma, bulky disease (defined as any site 7 cm or greater in size, or 3 or more sites 3 cm or greater in size), or progression. Participants must have received at least two prior systemic therapies for FL, or have relapsed or refractory FL who have no satisfactory alternative treatment options. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of zandelisib in combination with tazemetostat in participants <18 years of age, children are excluded from this study. ECOG performance status ≤2 (Karnofsky ≥60%). Participants must have adequate marrow function as defined below (unless abnormalities are considered related to marrow and/or splenic involvement by lymphoma): absolute neutrophil count ≥1,000/mcL platelets ≥75,000/mcL Participants must have adequate organ function as defined below (unless abnormalities are considered related to target organ involvement or compression by lymphoma): total bilirubin ≤ 1.5x institutional upper limit of normal (ULN) (Isolated bilirubin ≤3.0x ULN is acceptable if considered secondary to Gilbert's syndrome) AST(SGOT)/ALT(SGPT) ≤2.0 × institutional ULN Creatinine clearance ≥50 mL/min eGFR (Cockcroft-Gault) Participants with known history or current symptoms of cardiac disease should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better. The effects of zandelisib and tazemetostat on the developing human fetus are unknown. A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Nonchildbearing potential is defined as follows (by other than medical reasons): ≥45 years of age and has not had menses for >1 year Patients who have been amenorrhoeic for <1 year without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure. Women of childbearing potential must have a negative highly sensitive serum pregnancy test, and agree to repeat the highly sensitive serum pregnancy testing within 72 hours before the first dose of study intervention (if screening pregnancy test was not within 72 hours of dosing). Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term or persistent basis) OR agree to use a male condom, even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year when having sexual intercourse with a WOCBP (including pregnant females). Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia. At the discretion of the overall PI, participants with residual toxicities >Grade 1 may be considered eligible if in the opinion of the overall PI the residual toxicity is not likely to interfere with the safety or efficacy assessment of the investigational regimen. Participants who are receiving any other investigational agents. Participants must not have known central nervous system involvement by lymphoma. Participant must not have used an investigational drug or approved systemic lymphoma therapy with 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Steroids are permitted. Participant must not have received a PI3K inhibitor or EZH2 inhibitor. Participants must not have known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to zandelisib, tazemetostat, or drugs chemically related to zandelisib or tazemetostat, or any of the components of the study treatment. Participants must not have an uncontrolled intercurrent illness. Participants must not have an uncontrolled active infection. Participants must not have inflammatory bowel disease. Participants must not have active uncontrolled autoimmune disease. Participants must not have psychiatric illness/social situations that would limit compliance with study requirements. Participants must not have any serious and/or preexisting medical or other condition (including lab abnormalities) that could interfere with participant's safety in the opinion of the investigator. Women who are pregnant are excluded from this study because it is unknown if tazemetostat or zandelisib can cause embryo-fetal harm when administered to a pregnant woman. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with zandelisib and tazemetostat, breastfeeding should be discontinued if the mother is treated with zandelisib and tazemetostat. Participants must not have an active malignancy or systemic therapy for another malignancy within 3 years; local/regional therapy with curative intent such as surgical resection or localized radiation within 3 years of treatment is permitted; active prostate cancer that is considered low-risk and appropriate for continued active surveillance strategy is permitted. Additionally, adequately treated basal, squamous cell carcinoma, or non-melanomatous skin cancer, carcinoma in situ of the cervix, or superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, are permitted. Participant must be able to swallow pills. Participant must not have active uncontrolled HIV infection. Participants with HIV are eligible if disease is adequately controlled, defined by presence of both an undetectable viral load and a CD4 count >200. Participant must not have active hepatitis B infection. Participant with positive HBV core antibody or HBV surface antigen at screening are eligible if HBV viral load is negative by PCR and on appropriate antiviral therapy. Participant must not have active hepatitis C infection. Note: participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing. Coadministration of strong or moderate CYP3A inhibitors or inducers is not permitted. If a patient is taking a strong or moderate CYP3A inhibitor or inducer prior to starting treatment, this medication needs to be stopped for 1 week prior to initiation of protocol therapy to allow for a washout period.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Experimental

    Arm Label

    PHASE 1: ZANDELISIB + TAZEMETOSTAT

    Arm A: COMBINATION ZANDELISIB + TAZEMETOSTAT

    Arm B: Zandelisib and Tazemetostat

    Arm Description

    Phase 1 study (3+3 design), followed by a phase 2 expansion component For phase 1 portion, which follows the same dosing schedule as Arm A, there will not be any randomization. Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles. There will be 2 dose levels of tazemetostat.

    Participants randomized into Arm A of the phase 2 component will receive Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles

    Participants randomized into Arm B of the phase 2 component will receive Zandelisib oral, daily on predetermined days (Cycles 1-2) and predetermined days of cycle 3 and onwards up to 14 cycles. Tazemetostat, oral, twice daily on predetermined days of each cycle. This will begin on cycle 3 and will continue for up to 12 cycles.

    Outcomes

    Primary Outcome Measures

    Dose Limiting Toxicities Phase I
    Dose-limiting toxicity (DLT) is defined as an Adverse Event (AE) that meets all of the following criteria: Occurs during the 28 days of cycle 1 (DLT window); Is deemed at least possibly related to protocol therapy
    Complete Response Rate Phase II
    response classified per the 2014 Lugano criteria

    Secondary Outcome Measures

    Overall Response Rate
    Response classified per the 2014 Lugano criteria
    Median Progression-Free Survival
    summarized using Kaplan-Meier method
    Overall Survival
    summarized using Kaplan-Meier method
    Duration of Response
    The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented summarized using Kaplan-Meier method
    Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
    NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Full Information

    First Posted
    October 28, 2022
    Last Updated
    July 5, 2023
    Sponsor
    Jacob Soumerai, MD
    Collaborators
    MEI Pharma, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05604417
    Brief Title
    Zandelisib + Tazemetostat in R/R Follicular Lymphoma
    Official Title
    A Phase 1 Study With a Phase 2 Expansion Cohort of Zandelisib and Tazemetostat in Relapsed or Refractory Follicular Lymphoma
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Termination of Zandelisib clinical development globally
    Study Start Date
    January 2023 (Anticipated)
    Primary Completion Date
    December 1, 2024 (Anticipated)
    Study Completion Date
    December 1, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Jacob Soumerai, MD
    Collaborators
    MEI Pharma, Inc.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL) This research study involves Zandelisib in combination with Tazemetostat. MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.
    Detailed Description
    This is a phase 1 study of Zandelisib and Tazemetostat with a phase 2 expansion two-arm component in patients with relapsed or refractory follicular lymphoma (FL) grade 1-3A. - This research study involves Zandelisib in combination with Tazemetostat. This is the first time the drug combination of Zandelisib and Tazemetostat will be given to humans. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits Participants will receive study treatment as long as treatment is tolerated and the disease does not worsen. The maximum length of time on the study drug combination is 14 months. Participants will followed for up to 2 years. It is expected that about 34 people will take part in this research study. The U.S. Food and Drug Administration (FDA) has not approved zandelisib as a treatment for any disease. The U.S. FDA has approved tazemetostat as a treatment for relapsed or refractory follicular lymphoma as a single therapy. This is the first time this drug combination will be given to humans. This is a Phase I/II clinical trial. Participants will be asked to participate in either the Phase I part or Phase II part of this clinical trial. A Phase I clinical trial tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. A Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
    Keywords
    Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    PHASE 1: ZANDELISIB + TAZEMETOSTAT
    Arm Type
    Experimental
    Arm Description
    Phase 1 study (3+3 design), followed by a phase 2 expansion component For phase 1 portion, which follows the same dosing schedule as Arm A, there will not be any randomization. Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles. There will be 2 dose levels of tazemetostat.
    Arm Title
    Arm A: COMBINATION ZANDELISIB + TAZEMETOSTAT
    Arm Type
    Experimental
    Arm Description
    Participants randomized into Arm A of the phase 2 component will receive Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles
    Arm Title
    Arm B: Zandelisib and Tazemetostat
    Arm Type
    Experimental
    Arm Description
    Participants randomized into Arm B of the phase 2 component will receive Zandelisib oral, daily on predetermined days (Cycles 1-2) and predetermined days of cycle 3 and onwards up to 14 cycles. Tazemetostat, oral, twice daily on predetermined days of each cycle. This will begin on cycle 3 and will continue for up to 12 cycles.
    Intervention Type
    Drug
    Intervention Name(s)
    TAZEMETOSTAT
    Other Intervention Name(s)
    TAZVERIK
    Intervention Description
    Dosage and treatment timings per protocol
    Intervention Type
    Drug
    Intervention Name(s)
    Zandelisib
    Other Intervention Name(s)
    ME-401
    Intervention Description
    Dosage and treatment timings per protocol
    Primary Outcome Measure Information:
    Title
    Dose Limiting Toxicities Phase I
    Description
    Dose-limiting toxicity (DLT) is defined as an Adverse Event (AE) that meets all of the following criteria: Occurs during the 28 days of cycle 1 (DLT window); Is deemed at least possibly related to protocol therapy
    Time Frame
    Up to 28 days
    Title
    Complete Response Rate Phase II
    Description
    response classified per the 2014 Lugano criteria
    Time Frame
    up to 4 years
    Secondary Outcome Measure Information:
    Title
    Overall Response Rate
    Description
    Response classified per the 2014 Lugano criteria
    Time Frame
    Up to 4 years
    Title
    Median Progression-Free Survival
    Description
    summarized using Kaplan-Meier method
    Time Frame
    as the time from registration to the earlier of progression or death due to any cause up to 4 years
    Title
    Overall Survival
    Description
    summarized using Kaplan-Meier method
    Time Frame
    as the time from registration to death due to any cause, or censored at date last known alive up to 4 years
    Title
    Duration of Response
    Description
    The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented summarized using Kaplan-Meier method
    Time Frame
    Up to 4 years
    Title
    Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
    Description
    NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
    Time Frame
    baseline up to 4 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Participants must have biopsy-proven relapsed or refractory FL grade 1-2 or 3A by WHO criteria. Participants must require therapy based on: symptomatic disease, threatened end-organ dysfunction, compressive disease, cytopenias secondary to lymphoma, bulky disease (defined as any site 7 cm or greater in size, or 3 or more sites 3 cm or greater in size), or progression. Participants must have received at least two prior systemic therapies for FL, or have relapsed or refractory FL who have no satisfactory alternative treatment options. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of zandelisib in combination with tazemetostat in participants <18 years of age, children are excluded from this study. ECOG performance status ≤2 (Karnofsky ≥60%). Participants must have adequate marrow function as defined below (unless abnormalities are considered related to marrow and/or splenic involvement by lymphoma): absolute neutrophil count ≥1,000/mcL platelets ≥75,000/mcL Participants must have adequate organ function as defined below (unless abnormalities are considered related to target organ involvement or compression by lymphoma): total bilirubin ≤ 1.5x institutional upper limit of normal (ULN) (Isolated bilirubin ≤3.0x ULN is acceptable if considered secondary to Gilbert's syndrome) AST(SGOT)/ALT(SGPT) ≤2.0 × institutional ULN Creatinine clearance ≥50 mL/min eGFR (Cockcroft-Gault) Participants with known history or current symptoms of cardiac disease should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better. The effects of zandelisib and tazemetostat on the developing human fetus are unknown. A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Nonchildbearing potential is defined as follows (by other than medical reasons): ≥45 years of age and has not had menses for >1 year Patients who have been amenorrhoeic for <1 year without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure. Women of childbearing potential must have a negative highly sensitive serum pregnancy test, and agree to repeat the highly sensitive serum pregnancy testing within 72 hours before the first dose of study intervention (if screening pregnancy test was not within 72 hours of dosing). Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term or persistent basis) OR agree to use a male condom, even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year when having sexual intercourse with a WOCBP (including pregnant females). Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia. At the discretion of the overall PI, participants with residual toxicities >Grade 1 may be considered eligible if in the opinion of the overall PI the residual toxicity is not likely to interfere with the safety or efficacy assessment of the investigational regimen. Participants who are receiving any other investigational agents. Participants must not have known central nervous system involvement by lymphoma. Participant must not have used an investigational drug or approved systemic lymphoma therapy with 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Steroids are permitted. Participant must not have received a PI3K inhibitor or EZH2 inhibitor. Participants must not have known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to zandelisib, tazemetostat, or drugs chemically related to zandelisib or tazemetostat, or any of the components of the study treatment. Participants must not have an uncontrolled intercurrent illness. Participants must not have an uncontrolled active infection. Participants must not have inflammatory bowel disease. Participants must not have active uncontrolled autoimmune disease. Participants must not have psychiatric illness/social situations that would limit compliance with study requirements. Participants must not have any serious and/or preexisting medical or other condition (including lab abnormalities) that could interfere with participant's safety in the opinion of the investigator. Women who are pregnant are excluded from this study because it is unknown if tazemetostat or zandelisib can cause embryo-fetal harm when administered to a pregnant woman. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with zandelisib and tazemetostat, breastfeeding should be discontinued if the mother is treated with zandelisib and tazemetostat. Participants must not have an active malignancy or systemic therapy for another malignancy within 3 years; local/regional therapy with curative intent such as surgical resection or localized radiation within 3 years of treatment is permitted; active prostate cancer that is considered low-risk and appropriate for continued active surveillance strategy is permitted. Additionally, adequately treated basal, squamous cell carcinoma, or non-melanomatous skin cancer, carcinoma in situ of the cervix, or superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, are permitted. Participant must be able to swallow pills. Participant must not have active uncontrolled HIV infection. Participants with HIV are eligible if disease is adequately controlled, defined by presence of both an undetectable viral load and a CD4 count >200. Participant must not have active hepatitis B infection. Participant with positive HBV core antibody or HBV surface antigen at screening are eligible if HBV viral load is negative by PCR and on appropriate antiviral therapy. Participant must not have active hepatitis C infection. Note: participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing. Coadministration of strong or moderate CYP3A inhibitors or inducers is not permitted. If a patient is taking a strong or moderate CYP3A inhibitor or inducer prior to starting treatment, this medication needs to be stopped for 1 week prior to initiation of protocol therapy to allow for a washout period.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jacob D. Soumerai, MD
    Organizational Affiliation
    Massachusetts General Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
    IPD Sharing Time Frame
    Data can be shared no earlier than 1 year following the date of publication
    IPD Sharing Access Criteria
    Contact the Partners Innovations team at http://www.partners.org/innovation

    Learn more about this trial

    Zandelisib + Tazemetostat in R/R Follicular Lymphoma

    We'll reach out to this number within 24 hrs